Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

ed to enter into another alliance with Ipsen. This collaboration is an opportunity to grow our pipeline in oncology, our area of expertise. We believe that Debio 0931 may have applications in the treatment of various types of cancer which will increase the quality of life of many cancer patients."

About the partnership

The collaboration between Ipsen and Debiopharm started in 1983 with regards to LHRH analogues, in particular for the triptorelin analogue Decapeptyl(R) (also known as Pamoreline(R) and Diphereline(R)). In October 2007, their partnership was extended to grant Ipsen access to future sustained-release formulations of Decapeptyl(R) developed by Debiopharm, among which a 6-month sustained release formulation that was filed in Europe in September 2008, for the treatment of locally advanced or metastatic prostate cancer. Decapeptyl(R) 1 and 3-month formulations are currently commercialised in more than 60 countries worldwide, including 25 in Europe and they have generated almost EUR 248million in sales in 2008.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partne
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 /CNW/ - Softchoice, a leading North American IT solutions and ... recipient of two Cisco® Partner Summit Country awards. ... and Security Partner of the Year for Canada ... week in Montreal . ... partner awards at this year,s conference," said David MacDonald ...
(Date:5/1/2015)... -- According to a new market ... by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by ... Analysis & Global Forecast to 2019", published by ... Market for the forecast period of 2014 to ... Billion by 2019 from $1.425 Billion in 2014, ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology , ... an update on its Ebola antiviral therapy program. ... candidates, TMR004, is currently being evaluated and considered by ... battle against Ebola. During the first quarter of 2015, ... Meeting To Accelerate The Evaluation of Potential Treatments and ...
(Date:4/30/2015)... 30, 2015 Oxford Finance LLC ("Oxford"), a ... sciences and healthcare services companies, today announced the closing ... with Celula, Inc., a diagnostic testing company focused on ... patient care and improved outcomes.  Proceeds of the loan ... the commercialization of its products in the U.S. and ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Oxford Finance Provides $10 Million Debt Financing to Celula 2
... 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... the Company submitted its plan to cure stock price ... New York Stock Exchange ("NYSE") on October 5, 2011. ... American Oriental Bioengineering, Inc. is a pharmaceutical ...
... Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that ... trial sites by the end of the quarter, with ... now open and active where patients can enroll in ... for Glioblastoma multiforme (GBM), the most lethal form of ...
... Researchers recently isolated 63 unique dust particles from their ... chemists were testing a new kind of sensor when dust ... measure the composition of single dust particles. In a ... , they describe how the discovery could aid the study ...
Cached Biology Technology:NORTHWEST BIO Announces Positive Third Quarter Progress 2NORTHWEST BIO Announces Positive Third Quarter Progress 3NORTHWEST BIO Announces Positive Third Quarter Progress 41 room -- 63 different dust particles? Researchers aim to build dust library 21 room -- 63 different dust particles? Researchers aim to build dust library 3
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... from the University of Sheffield has discovered that the deep open ... currently the most under-explored area of the sea, and the one ... today (2 August 2010) in the journal PLoS ONE , ... most of our knowledge of marine biodiversity comes from the shallow ...
... AURORA, Colo. (Aug. 2, 2010) -- As if ... of Colorado School of Medicine has discovered a new type ... fat cells arise from stem cells in the bone marrow ... are termed bone marrow progenitor-derived adipocytes. The discovery also revealed ...
... scientists at the University of California, Davis and the University ... disease by preventing brain neurons from dying in response to ... in the April, 2010 issue of Apoptosis . ... amyloid toxicity and injury due to lack of oxygen. Neuroglobin ...
Cached Biology News:Study finds deep, open ocean is vastly under-explored 2Scientists at University of Colorado Anschutz Medical Campus discover new fat cell 2Scientists discover how neuroglobin protects against Alzheimer's 2
... of robotic workstations is designed for laboratories ... the ideal automation platform for routine sample ... procedures, improving throughput, process consistency and safety. ... software allows you to control the robotic ...
... utilizes a silica based spin filter membrane to ... desired DNA band is cut from an agarose ... unit. The gel slice is melted irreversibly in ... is bound to the silica spin filter membrane ...
... to HDAC4 - ChIP Grade HDAC4 ... mammalian histone deacetylases, which consists of 1084 ... highly similar to the deacetylase domain of ... between the nucleus and cytoplasm in a ...
... pACHLT-A-BFP Baculovirus Transfer Vector is a derivative of ... gene for blue fluorescent protein (BFP), followed by ... (MCS).,Foreign genes are expressed as BFP-6xHis fusion proteins ... enzyme,sites (EcoR I, Stu I, Sac I, Not ...
Biology Products: